Skip to main content
letter
. 2020 Jul 8;81(3):e18–e19. doi: 10.1016/j.jinf.2020.07.007

Table 1.

Demographic, clinical and outcome data for patients with confirmed COVID-19 re-admitted to hospital.

All patients Patients discharged Patients readmitted Readmitted dyspnoeic cohort
729 391 25 14
Demographics
Age: median (I) 66(53–80) 59(48–76) 73(58–82) 68(57–81)
Sex:
Male 429/729 15(60.0) 8(57.1)
Female 300/729 10(40.0) 6(42.9)
Ethnicity 533 307 21 11
BAME: absolute(%) 324(60.8) 192(62.5) 12(57.1) 8(72.7)
White European: absolute(%) 209(39.2) 115(37.5) 9(42.9) 3(27.3)
Co-morbidities:
Any co-morbidity 24(96.0) 14(100.0)
Hypertension 16(64.0) 11(78.5)
Diabetes 6(24.0) 4(25.0)
Admission 1
Peak neutrophil count: median (l) 6.97 (4.99–8.95) 6(4.36–7.88) 5.55(4.65–7.34) 5.53 (4.5625–5.95)
Nadir lymphocyte count: median (l) 0.77(0.54–1.09) 1(0.64–1.15) 0.82 (0.66–1.05) 0.83 (0.70–0.91)
Peakferritin: median (l) 819(417–1640) 692(324.25–1300.25392(184–846.5) 414(213.5–828.25)
PeakCRP: median (l) 85.4 (53.3–150.18) 72(40.05–94.65) 62.7(16.15–84.85) 61.7(39.68–80.10)
lw admission? 102(14.0) 15(3.84) 2(8.0) 0(0.0)
Length ofstayfrom COVID diagnosis: median (l) 6(3–10) 7(4–11) 6(1–9) 5(0–8)
Discharge 1
Sp02 on discharge: median (l) 94.5 (92.25–96) 94.0(92.0–96.0)
Readmisslon
Timeto readmission 10(6–15) 11(7.5–14.5)
Reason for readmission
SOB: absolute (%) 13(52.0) NA
Other: absolute(%) 12(48.0) NA
Sp02 on admission 90.5 (80.75–95) 82(77.0–89.25)
Mmission neutrophil count: median (l) 6.09 (5.07–10.93) 6.00 (5.05–11.00)
Mmission lymphocytecount: median (l) 1.11 (0.79–1.85) 1(0.6–1.27)
Mmission ferritin: median (l) 597 (102–1158) 378(87.5–890.25)
Mmission CRP: median (l) 45(5.5–92) 76(6.65–197.5)
CXR 24 14
COVID: absolute (%) 12(50.0) 8(57.1)
Non-COVID: absolute(%) 6(25.0) 5(35.7)
Normal: absolute(%) 6(25.0) 1(7.1)
Outcome of admission 2
Died/End of Life: absolute (%) 6(24.0) 4(28.6)
Recovered: absolute (%) 16(64.0) 8(57.1)
Still admitted: absolute (%) 3(12.50) 2(14.3)
Transferred: absolute(%) 0(0) 0